Comparison of lenograstim and filgrastim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy

Current Medical Research and Opinion

Volumn 19, Issue 8, 2003, Pages 753-759

  Kim, In Hyang ^a   Park, Sung Kyu ^b   Suh, Ok Kyung ^a   Oh, Jung Mi ^c  

^a Seoul National University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Sookmyung Women's University   (South Korea)

Author keywords

Filgrastim; G CSF; Lenograstim; Neutropenia; PBSCT

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; CASE-CONTROL STUDIES; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0345276665     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002531     Document Type: Article

References (27)

1. Shea TC. Introduction: current issues in high-dose chemotherapy and stem cell support. Bone Marrow Transplant 1999;23:S1-S5
2. Schmidt N, Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353-7
3. Gillespie TW, Hillyer CD. Peripheral blood progenitor cells for marrow reconstitution: mobilization and collection strategies. Transfusion 1996;36:611-24
4. To LB, Roberts MM, Haylock DN, et al. Comparison of hematological recovery times and supportive care requirements of autologous phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-84
5. Beyer J, Schwella N, Zingsem J, et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995;13:1328-35
6. Hendon PR, Liang H, Beck-Wirth G, et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992;9:285-91
7. Bearman SI, Appelbaum FR, Back, et al. Regimen-related toxicity and early post-transplant survival in patients undergoing marrow transplantation for lymphoma. J Clin Oncol 1989;7:1288-94
8. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
9. Schmitz N, Dreger P, Zander AR, et al. Results of randomized, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261-6
10. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony-stimulating factor. Blood 1993;81:3158-63
11. Sheridan WP, Wolf M, Lusk J, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high dose chemotherapy and autologous bone marrow transplantation in. Lancet 1989;2:891-5
12. Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989;7:1791-9
13. Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factors after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8
14. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8
15. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4
16. Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemotopoietic progenitor cell compartment in man. Lancet 1988;1:1194-8
17. Vigorito AC, Azevedo WM, Marques JF, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998;22:1145-51
18. Chao NJ, Schriber JR, Grimes K, et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-5
19. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
20. Mostyn G, Burges AW. Hematopoietic growth factors: a review. Cancer Res 1988;48:5624-37
21. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. N Engl J Med 1992;327:28-35,99-106
22. Kubota N, Orita T, Hattori K. Structural characterization of natural and recombinant human granulocyte colony-stimulating factor. J Biochem 1990;107:486-92
23. Nissen C, Dalle Carbonare V, Moser Y. In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest 1994;7:346-52
24. Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474-9
25. Rebischung JN, Deletie E, Larroutourou P, et al. Comparative study of filgrastim and lenograstim. Clinical and economic studies. Proc Am Soc Clin Oncol 1994;14:260 (Abstr 713)
26. Saccardi R, Avanzi G, Brzzini R, et al. Mobilization of PBPC for hematological rescue: comparison between glycosylated and nonglycosylated G-CSF. Bone Marrow Transplant 1997;19;S1(Suppl 1; Abstr 43)
27. Stahel RA, Jost LM, Honegger H, Betts E, Goebel MEM, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 μg/kg/day and 10 μg/kg/day following high dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997;15:1730-5